Modular Medical, Inc., a development-stage medical device company, focuses on the design, development and marketing of insulin pumps for people with insulin-dependent diabetes. The company is headquartered in San Diego, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-25.53M |
| Operating Margin | 0.00% |
| Return on Equity | -247.90% |
| Return on Assets | -129.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.93 |
| Price-to-Book | 2.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.15M |
| Float | $7.14M |
| % Insiders | 1.69% |
| % Institutions | 28.08% |
Volatility is currently contracting
Commercial-stage medical device manufacturer Modular Medical Inc. (NASDAQ:MODD) recently signed a significant contract with a national U.S. pharmacy benefit manager (PBM).
SAN DIEGO, CA / ACCESS Newswire / September 4, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company's Pivot insulin delivery system is now available through the national PBM.
Clearance Covers Software Enhancements for Greater Patient Flexibility and Pivot Customization SAN DIEGO, CA / ACCESS Newswire / September 3, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system's functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades. "We are pleased that this clearance was received in advance of our planned fourth quarter launch.
Meet with Modular Medical CEO Jeb Besser. Discover The Pivot tubeless patch pump, a simple, wearable insulin delivery platform designed to provide continuous subcutaneous insulin infusion with both basal and bolus insulin delivery over a three-day wear period.
SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Modular Medical, Inc ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that management will host a booth at the Association of Diabetes Care & Education Specialists 2026 Annual Conference (the "Conference") in Columbus, Ohio, from August 7-10, 2026, where they will showcase the new Pivot tubeless insulin patch pump. Conference attendees will have the opportunity to experience live demonstrations of the tubeless Pivot insulin pump and see firsthand how its intuitive, simplified design can expand access to insulin pump therapy.
First Phase of Strategic Rollout Targets Markets with Leading Insulin Pump Prescribers and Strong New Pump Adoption. Inizio will Provide Commercialization Expertise to Accelerate Awareness and Adoption of the Pivot Pump.
- Council to Provide Strategic Clinical Guidance on Commercialization, Patient Identification, Workflow Integration, and Evidence Generation SAN DIEGO, CA / ACCESS Newswire / July 23, 2026 / Modular Medical, Inc, ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company's clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council.
Pilot Combines Clinician Guided Phenotypes with IMO Health's Unique Terminology Identifiers to Help Clinicians Easily Identify Patients Most Likely to Benefit from Pivot Insulin Pump Therapy Advancing Towards Fourth Quarter Commercial Launch of Pivot Pump SAN DIEGO, CA AND ROSEMONT, IL / ACCESS Newswire / July 16, 2026 / Modular Medical, Inc., ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced an important pilot collaboration with IMO Health, whose expert-curated clinical terminology and accountable healthcare AI solutions are used across nearly all U.S. health systems to transform healthcare data into trusted clinical context. Through this pilot, Modular Medical and IMO Health expect to develop a deployable terminology-powered phenotypic algorithm designed to identify diabetes patients who may benefit from insulin pump therapy directly within the electronic health record (EHR).
Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel. "From the earliest stages of development, our goal has been to develop a practical and affordable insulin pumping solution that removes many of the barriers preventing insulin-dependent individuals from transitioning from multiple daily injections to pump therapy," said Jeb Besser, CEO of Modular Medical.
97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026 SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MODD and any ticker you trade — then tracks every position and per-strategy win rate.
